Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.49 |
| ▸ | HPGD | P15428 | 3/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.48 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.45 |
| ▸ | MEN1 | O00255 | 2/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | NPC1 | O15118 | 3/20 | 0.45 |
| ▸ | RAB9A | P51151 | 2/20 | 0.45 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | GLA | P06280 | 1/20 | 0.43 |
| ▸ | PKM | P14618 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30450132 | 0.87 | ALDH1A1 (0.49) | ALDH1A1HPGDCYP1A2CYP3A4CYP2D6 | |
| SCHEMBL17080016 | 0.87 | ALDH1A1 (0.49) | ALDH1A1HPGDCYP1A2CYP3A4CYP2D6 | |
| SCHEMBL16542450 | 0.85 | ALDH1A1 (0.53) | ALDH1A1HPGDCYP1A2CYP3A4CYP2D6 | |
| SCHEMBL16178892 | 0.83 | BRD9 (0.46) | ALDH1A1HPGDCYP1A2CYP3A4CYP2D6 | |
| SCHEMBL29710158 | 0.82 | ALDH1A1 (0.50) | ALDH1A1HPGDCYP1A2CYP3A4CYP2D6 | |
| SCHEMBL6029717 | 0.82 | ALDH1A1 (0.50) | ALDH1A1HPGDCYP1A2CYP3A4CYP2D6 | |
| SCHEMBL7812949 | 0.81 | LMNA (0.54) | ALDH1A1HPGDCYP1A2CYP3A4CYP2D6 | |
| SCHEMBL31704180 | 0.81 | ALDH1A1 (0.49) | ALDH1A1HPGDCYP1A2CYP3A4CYP2D6 | |
| SCHEMBL21515221 | 0.80 | BRD9 (0.49) | ALDH1A1HPGDCYP1A2CYP3A4CYP2D6 | |
| SCHEMBL6985580 | 0.80 | BRD9 (0.49) | ALDH1A1HPGDCYP1A2CYP3A4CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9376436-B2 | 2-(pyridin-2yl)-1, 7-diaza-spiro [4.4] nonane-6-one compound as voltage-gated sodium channels modulators | Convergence Pharmaceuticals Limited (GB) | 2016-06-28 | — | — | US | disclosed |
| EP-2794612-B1 | 2-(PYRIDIN-2YL)-1,7-DIAZA-SPIRO[4.4]NONANE-6-ONE COMPOUNDS AS VOLTAGE-GATED SODIUM CHANNELS MODULATORS | CONVERGENCE PHARMACEUTICALS (GB) | 2016-04-06 | — | — | EP | disclosed |
| US-20150225400-A1 | 2 - (PYRIDIN- 2YL)- 1, 7 -DIAZA-SPIRO [4.4] NONANE- 6 -ONE COMPOUND AS VOLTAGE-GATED SODIUM CHANNELS MODULATORS | Convergence Pharmaceuticals Limited (GB) | 2015-08-13 | — | — | US | disclosed |
| EP-2794612-A1 | 2 - (PYRIDIN- 2YL) - 1, 7 -DIAZA- SPIRO [4.4]NONANE- 6 -ONE COMPOUNDS AS VOLTAGE - GATED SODIUM CHANNELS MODULATORS | Convergence Pharmaceuticals Limited (GB) | 2014-10-29 | — | — | EP | disclosed |
| WO-2013093497-A1 | 2 - (PYRIDIN- 2YL) - 1, 7 -DIAZA- SPIRO [4.4] NONANE- 6 -ONE COMPOUNDS AS VOLTAGE - GATED SODIUM CHANNELS MODULATORS | Convergence Pharmaceuticals Limited (GB) | 2013-06-27 | — | — | WO | disclosed |
| US-20130053372-A1 | 5-HT RECEPTOR MODULATORS | CAMBRIDGE ENTERPRISE LIMITED | 2013-02-28 | — | — | US | disclosed |
| US-20130053372-A1 | 5-HT RECEPTOR MODULATORS | CAMBRIDGE ENTERPRISE LIMITED | 2013-02-28 | — | — | US | disclosed |
| WO-2011098776-A1 | 5-HT RECEPTOR MODULATORS | CAMBRIDGE ENTERPRISE LIMITED (GB) | 2011-08-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130053372-A1 | 5-HT RECEPTOR MODULATORS | HTR1B, HTR5A, HTR1A | ALDH1A1 987/4885HPGD 643/4885CYP1A2 627/4885 |
| US-20150225400-A1 | 2 - (PYRIDIN- 2YL)- 1, 7 -DIAZA-SPIRO [4.4] NONANE- 6 -ONE COMPOUND AS VOLTAGE-GATED SODIUM CHANNELS MODULATORS | SCN1A, SCN2A, SCN1B | ALDH1A1 705/4885HPGD 521/4885CYP1A2 1261/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.